$NKTR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NEKTAR THERAPEUTICS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NEKTAR THERAPEUTICS. Get notifications about new insider transactions in NEKTAR THERAPEUTICS for free.
Page: < prev 1 2 3 4 5 6 7 8 ... 12 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 5.14 | 15,000 | 77,100 | 15,000 | |
Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 14.26 | 10,000 | 142,600 | 20,000 | |
Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | M | 14.26 | 10,000 | 142,600 | 20,000 | |
Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 92.14 | 15,000 | 1,382,100 | 274,223 | 289.2 K to 274.2 K (-5.19 %) |
Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 92.14 | 15,000 | 1,382,100 | 274,223 | 289.2 K to 274.2 K (-5.19 %) |
Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Buy | M | 5.14 | 15,000 | 77,100 | 289,223 | 274.2 K to 289.2 K (+5.47 %) |
Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Buy | M | 5.14 | 15,000 | 77,100 | 289,223 | 274.2 K to 289.2 K (+5.47 %) |
Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 92.15 | 10,000 | 921,500 | 274,223 | 284.2 K to 274.2 K (-3.52 %) |
Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 92.15 | 10,000 | 921,500 | 274,223 | 284.2 K to 274.2 K (-3.52 %) |
Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Buy | M | 14.26 | 10,000 | 142,600 | 284,223 | 274.2 K to 284.2 K (+3.65 %) |
Apr 09 2018 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Buy | M | 14.26 | 10,000 | 142,600 | 284,223 | 274.2 K to 284.2 K (+3.65 %) |
Mar 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Option Exercise | M | 9.24 | 10,000 | 92,400 | 30,000 | |
Mar 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Option Exercise | M | 5.14 | 27,400 | 140,836 | 0 | |
Mar 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Option Exercise | M | 5.14 | 2,600 | 13,364 | 27,400 | |
Mar 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Sell | S | 97.41 | 37,400 | 3,643,134 | 40,500 | 77.9 K to 40.5 K (-48.01 %) |
Mar 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Buy | M | 9.24 | 10,000 | 92,400 | 77,900 | 67.9 K to 77.9 K (+14.73 %) |
Mar 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Buy | M | 5.14 | 27,400 | 140,836 | 67,900 | 40.5 K to 67.9 K (+67.65 %) |
Mar 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Sell | S | 100.30 | 2,600 | 260,780 | 40,500 | 43.1 K to 40.5 K (-6.03 %) |
Mar 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Buy | M | 5.14 | 2,600 | 13,364 | 43,100 | 40.5 K to 43.1 K (+6.42 %) |
Mar 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | S | 100.45 | 100,144 | 10,059,465 | 167,513 | 267.7 K to 167.5 K (-37.42 %) |
Mar 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | S | 98.29 | 120,000 | 11,794,800 | 267,657 | 387.7 K to 267.7 K (-30.96 %) |
Feb 20 2018 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | S | 82.94 | 2,545 | 211,082 | 68,857 | 71.4 K to 68.9 K (-3.56 %) |
Feb 20 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 82.94 | 12,788 | 1,060,637 | 237,147 | 249.9 K to 237.1 K (-5.12 %) |
Feb 20 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | S | 82.94 | 4,879 | 404,664 | 387,657 | 392.5 K to 387.7 K (-1.24 %) |
Feb 20 2018 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | S | 82.94 | 3,477 | 288,382 | 99,739 | 103.2 K to 99.7 K (-3.37 %) |
Feb 20 2018 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | S | 82.94 | 2,875 | 238,453 | 80,261 | 83.1 K to 80.3 K (-3.46 %) |
Feb 20 2018 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 82.94 | 2,426 | 201,212 | 67,394 | 69.8 K to 67.4 K (-3.47 %) |
Feb 02 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Option Exercise | M | 11.34 | 120,000 | 1,360,800 | 0 | |
Feb 02 2018 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Buy | M | 11.34 | 120,000 | 1,360,800 | 392,536 | 272.5 K to 392.5 K (+44.03 %) |
Jan 24 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 11.34 | 83,333 | 944,996 | 0 | |
Jan 24 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 75.82 | 83,333 | 6,318,308 | 249,935 | 333.3 K to 249.9 K (-25.00 %) |
Jan 24 2018 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 11.34 | 83,333 | 944,996 | 333,268 | 249.9 K to 333.3 K (+33.34 %) |
Jan 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | WINGER DENNIS L | Director | Option Exercise | M | 11.97 | 11,250 | 134,663 | 0 | |
Jan 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | WINGER DENNIS L | Director | Option Exercise | M | 11.97 | 22,500 | 269,325 | 0 | |
Jan 08 2018 | NKTR | NEKTAR THERAPEUTIC ... | WINGER DENNIS L | Director | Buy | M | 11.97 | 33,750 | 403,988 | 77,000 | 43.3 K to 77 K (+78.03 %) |
Jan 04 2018 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Option Exercise | M | 14.26 | 30,000 | 427,800 | 0 | |
Jan 04 2018 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Sell | S | 58.66 | 30,000 | 1,759,800 | 40,500 | 70.5 K to 40.5 K (-42.55 %) |
Jan 04 2018 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Buy | M | 14.26 | 30,000 | 427,800 | 70,500 | 40.5 K to 70.5 K (+74.07 %) |
Dec 19 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | A | 56.90 | 151,250 | 8,606,125 | 151,250 | |
Dec 19 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 0.00 | 60,500 | 0 | 249,935 | 189.4 K to 249.9 K (+31.94 %) |
Dec 19 2017 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | A | 56.90 | 26,250 | 1,493,625 | 26,250 | |
Dec 19 2017 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Grant | A | 0.00 | 10,400 | 0 | 71,402 | 61 K to 71.4 K (+17.05 %) |
Dec 19 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
Dec 19 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Grant | A | 0.00 | 26,000 | 0 | 272,536 | 246.5 K to 272.5 K (+10.55 %) |
Dec 19 2017 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
Dec 19 2017 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Grant | A | 0.00 | 26,000 | 0 | 103,216 | 77.2 K to 103.2 K (+33.67 %) |
Dec 19 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | A | 56.90 | 37,500 | 2,133,750 | 37,500 | |
Dec 19 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Grant | A | 0.00 | 15,000 | 0 | 83,136 | 68.1 K to 83.1 K (+22.01 %) |
Dec 19 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | A | 56.90 | 65,000 | 3,698,500 | 65,000 | |
Dec 19 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Grant | A | 0.00 | 26,000 | 0 | 69,820 | 43.8 K to 69.8 K (+59.33 %) |
Dec 15 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 11.34 | 83,333 | 944,996 | 83,333 | |
Dec 15 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 55.69 | 83,333 | 4,640,815 | 189,435 | 272.8 K to 189.4 K (-30.55 %) |
Dec 15 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 11.34 | 83,333 | 944,996 | 272,768 | 189.4 K to 272.8 K (+43.99 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Option Exercise | A | 14.41 | 37,500 | 540,375 | 37,500 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | D | 44.23 | 5,289 | 233,932 | 60,549 | 65.8 K to 60.5 K (-8.03 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Grant | A | 0.00 | 15,000 | 0 | 65,838 | 50.8 K to 65.8 K (+29.51 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | A | 14.41 | 137,500 | 1,981,375 | 137,500 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | D | 44.23 | 18,069 | 799,192 | 189,435 | 207.5 K to 189.4 K (-8.71 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Grant | A | 0.00 | 55,000 | 0 | 207,504 | 152.5 K to 207.5 K (+36.06 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Option Exercise | A | 14.41 | 50,000 | 720,500 | 50,000 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | D | 44.23 | 6,620 | 292,803 | 246,536 | 253.2 K to 246.5 K (-2.61 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Grant | A | 0.00 | 20,000 | 0 | 253,156 | 233.2 K to 253.2 K (+8.58 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Option Exercise | A | 14.41 | 50,000 | 720,500 | 50,000 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | D | 44.23 | 6,698 | 296,253 | 76,716 | 83.4 K to 76.7 K (-8.03 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Grant | A | 0.00 | 20,000 | 0 | 83,414 | 63.4 K to 83.4 K (+31.54 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | A | 14.41 | 37,500 | 540,375 | 37,500 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | D | 44.23 | 5,597 | 247,555 | 67,636 | 73.2 K to 67.6 K (-7.64 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Grant | A | 0.00 | 15,000 | 0 | 73,233 | 58.2 K to 73.2 K (+25.76 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Option Exercise | A | 14.41 | 50,000 | 720,500 | 50,000 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Sell | D | 44.23 | 5,022 | 222,123 | 56,553 | 61.6 K to 56.6 K (-8.16 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Grant | A | 0.00 | 20,000 | 0 | 61,575 | 41.6 K to 61.6 K (+48.11 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | A | 14.41 | 43,750 | 630,438 | 43,750 | |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | D | 44.23 | 4,782 | 211,508 | 43,820 | 48.6 K to 43.8 K (-9.84 %) |
Nov 17 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Grant | A | 0.00 | 17,500 | 0 | 48,602 | 31.1 K to 48.6 K (+56.27 %) |
Nov 15 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Option Exercise | M | 9.24 | 25,000 | 231,000 | 0 | |
Nov 15 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | S | 37.78 | 15,910 | 601,080 | 233,156 | 249.1 K to 233.2 K (-6.39 %) |
Nov 15 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Buy | M | 9.24 | 25,000 | 231,000 | 249,066 | 224.1 K to 249.1 K (+11.16 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | M | 10.69 | 17,300 | 184,937 | 0 | |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | M | 10.69 | 5,117 | 54,701 | 17,300 | |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | M | 25.51 | 17,300 | 441,323 | 58,233 | 75.5 K to 58.2 K (-22.90 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Buy | M | 10.69 | 17,300 | 184,937 | 75,533 | 58.2 K to 75.5 K (+29.71 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | S | 25.07 | 5,117 | 128,283 | 58,233 | 63.4 K to 58.2 K (-8.08 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Buy | M | 10.69 | 5,117 | 54,701 | 63,350 | 58.2 K to 63.4 K (+8.79 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 9.53 | 300,000 | 2,859,000 | 0 | |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 9.53 | 75,409 | 718,648 | 300,000 | |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 9.53 | 20,914 | 199,310 | 375,409 | |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 30.09 | 300,000 | 9,027,000 | 31,102 | 331.1 K to 31.1 K (-90.61 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 9.53 | 300,000 | 2,859,000 | 331,102 | 31.1 K to 331.1 K (+964.57 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 25.78 | 75,409 | 1,944,044 | 31,102 | 106.5 K to 31.1 K (-70.80 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 9.53 | 75,409 | 718,648 | 106,511 | 31.1 K to 106.5 K (+242.46 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 24.98 | 20,914 | 522,432 | 31,102 | 52 K to 31.1 K (-40.21 %) |
Nov 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 9.53 | 20,914 | 199,310 | 52,016 | 31.1 K to 52 K (+67.24 %) |
Nov 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 11.34 | 83,334 | 945,008 | 166,666 | |
Nov 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 23.57 | 83,334 | 1,964,182 | 152,504 | 235.8 K to 152.5 K (-35.34 %) |
Nov 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 11.34 | 83,334 | 945,008 | 235,838 | 152.5 K to 235.8 K (+54.64 %) |
Oct 10 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 11.34 | 83,333 | 944,996 | 250,000 | |
Oct 10 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 24.20 | 83,333 | 2,016,659 | 152,504 | 235.8 K to 152.5 K (-35.33 %) |
Oct 10 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 11.34 | 83,333 | 944,996 | 235,837 | 152.5 K to 235.8 K (+54.64 %) |
Oct 10 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Option Exercise | M | 10.69 | 7,583 | 81,062 | 22,417 | |
Oct 10 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | S | 25.00 | 7,583 | 189,575 | 58,233 | 65.8 K to 58.2 K (-11.52 %) |
Oct 10 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Buy | M | 10.69 | 7,583 | 81,062 | 65,816 | 58.2 K to 65.8 K (+13.02 %) |
Oct 10 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Option Exercise | M | 9.53 | 43,677 | 416,242 | 396,323 | |
Oct 10 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 24.97 | 43,677 | 1,090,615 | 31,102 | 74.8 K to 31.1 K (-58.41 %) |
Oct 10 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Buy | M | 9.53 | 43,677 | 416,242 | 74,779 | 31.1 K to 74.8 K (+140.43 %) |
Oct 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Option Exercise | M | 11.34 | 120,000 | 1,360,800 | 0 | |
Oct 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | S | 24.45 | 120,000 | 2,934,000 | 63,414 | 183.4 K to 63.4 K (-65.43 %) |
Oct 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Buy | M | 11.34 | 120,000 | 1,360,800 | 183,414 | 63.4 K to 183.4 K (+189.23 %) |
Oct 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Option Exercise | M | 11.04 | 56,704 | 626,012 | 313,752 | |
Oct 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Option Exercise | M | 11.04 | 43,296 | 477,988 | 370,456 | |
Oct 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Sell | S | 24.21 | 56,704 | 1,372,804 | 41,575 | 98.3 K to 41.6 K (-57.70 %) |
Oct 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Buy | M | 11.04 | 56,704 | 626,012 | 98,279 | 41.6 K to 98.3 K (+136.39 %) |
Oct 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Sell | S | 24.04 | 43,296 | 1,040,836 | 41,575 | 84.9 K to 41.6 K (-51.01 %) |
Oct 03 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Buy | M | 11.04 | 43,296 | 477,988 | 84,871 | 41.6 K to 84.9 K (+104.14 %) |
Sep 25 2017 | NKTR | NEKTAR THERAPEUTIC ... | Lingnau Lutz | Director | Sell | S | 21.97 | 5,000 | 109,850 | 27,450 | 32.5 K to 27.5 K (-15.41 %) |
Sep 25 2017 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Sell | S | 21.86 | 4,000 | 87,440 | 40,500 | 44.5 K to 40.5 K (-8.99 %) |
Sep 25 2017 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Sell | S | 21.72 | 6,400 | 139,008 | 274,223 | 280.6 K to 274.2 K (-2.28 %) |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Option Exercise | A | 21.75 | 22,500 | 489,375 | 22,500 | |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Option Exercise | A | 21.75 | 33,750 | 734,063 | 33,750 | |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Grant | A | 0.00 | 9,000 | 0 | 22,500 | 13.5 K to 22.5 K (+66.67 %) |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Grant | A | 0.00 | 13,500 | 0 | 13,500 | 0 to 13.5 K |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Option Exercise | A | 21.75 | 22,500 | 489,375 | 22,500 | |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | KUEBLER CHRISTOPHER A | Director | Grant | A | 0.00 | 9,000 | 0 | 44,500 | 35.5 K to 44.5 K (+25.35 %) |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Option Exercise | A | 21.75 | 22,500 | 489,375 | 22,500 | |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Grant | A | 0.00 | 9,000 | 0 | 142,000 | 133 K to 142 K (+6.77 %) |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | Lingnau Lutz | Director | Option Exercise | A | 21.75 | 22,500 | 489,375 | 22,500 | |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | Lingnau Lutz | Director | Grant | A | 0.00 | 9,000 | 0 | 32,450 | 23.5 K to 32.5 K (+38.38 %) |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | Krivulka Joseph J | Director | Option Exercise | A | 21.75 | 22,500 | 489,375 | 22,500 | |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | Krivulka Joseph J | Director | Grant | A | 0.00 | 9,000 | 0 | 82,000 | 73 K to 82 K (+12.33 %) |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Option Exercise | A | 21.75 | 22,500 | 489,375 | 22,500 | |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | GREER R SCOTT | Director | Grant | A | 0.00 | 9,000 | 0 | 130,333 | 121.3 K to 130.3 K (+7.42 %) |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Option Exercise | A | 21.75 | 22,500 | 489,375 | 22,500 | |
Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | CHESS ROBERT | Director | Grant | A | 0.00 | 9,000 | 0 | 280,623 | 271.6 K to 280.6 K (+3.31 %) |
Sep 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 11.34 | 83,333 | 944,996 | 333,333 | |
Sep 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 21.54 | 83,333 | 1,794,993 | 152,504 | 235.8 K to 152.5 K (-35.33 %) |
Sep 08 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 11.34 | 83,333 | 944,996 | 235,837 | 152.5 K to 235.8 K (+54.64 %) |
Aug 18 2017 | NKTR | NEKTAR THERAPEUTIC ... | Thomsen Jillian B. | SVP & Chief Account ... | Sell | S | 19.32 | 2,648 | 51,159 | 50,838 | 53.5 K to 50.8 K (-4.95 %) |
Aug 18 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Option Exercise | M | 11.34 | 83,334 | 945,008 | 416,666 | |
Aug 18 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 19.25 | 83,334 | 1,604,180 | 152,504 | 235.8 K to 152.5 K (-35.34 %) |
Aug 18 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Buy | M | 11.34 | 83,334 | 945,008 | 235,838 | 152.5 K to 235.8 K (+54.64 %) |
Aug 18 2017 | NKTR | NEKTAR THERAPEUTIC ... | ROBIN HOWARD W | President & CEO | Sell | S | 19.32 | 8,380 | 161,902 | 152,504 | 160.9 K to 152.5 K (-5.21 %) |
Aug 18 2017 | NKTR | NEKTAR THERAPEUTIC ... | Nicholson John | SVP & Chief Operati ... | Sell | S | 19.32 | 3,177 | 61,380 | 224,066 | 227.2 K to 224.1 K (-1.40 %) |
Aug 18 2017 | NKTR | NEKTAR THERAPEUTIC ... | Labrucherie Gil M | SVP & Chief Financi ... | Sell | S | 19.32 | 3,177 | 61,380 | 63,414 | 66.6 K to 63.4 K (-4.77 %) |
Aug 18 2017 | NKTR | NEKTAR THERAPEUTIC ... | Hora Maninder | SVP Pharma Dev & Mf ... | Sell | S | 19.32 | 2,956 | 57,110 | 58,233 | 61.2 K to 58.2 K (-4.83 %) |
Aug 18 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Sell | S | 19.32 | 1,997 | 38,582 | 41,575 | 43.6 K to 41.6 K (-4.58 %) |
Aug 18 2017 | NKTR | NEKTAR THERAPEUTIC ... | Doberstein Stephen K | SVP & Chief Scienti ... | Sell | S | 19.32 | 1,701 | 32,863 | 31,102 | 32.8 K to 31.1 K (-5.19 %) |
Aug 14 2017 | NKTR | NEKTAR THERAPEUTIC ... | WHITFIELD ROY A | Director | Buy | P | 17.95 | 35,000 | 628,250 | 133,000 | 98 K to 133 K (+35.71 %) |
Jul 20 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Option Exercise | M | 11.04 | 54,920 | 606,317 | 413,752 | |
Jul 20 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Sell | S | 21.10 | 54,920 | 1,158,812 | 43,572 | 98.5 K to 43.6 K (-55.76 %) |
Jul 20 2017 | NKTR | NEKTAR THERAPEUTIC ... | Gergel Ivan P. | SVP & Chief Medical ... | Buy | M | 11.04 | 54,920 | 606,317 | 98,492 | 43.6 K to 98.5 K (+126.04 %) |
Jul 18 2017 | NKTR | NEKTAR THERAPEUTIC ... | Lingnau Lutz | Director | Option Exercise | M | 14.26 | 30,000 | 427,800 | 0 |